Trisha Suppes, MD, PhD

Clinical Focus

• Psychiatry

Administrative Appointments

• Member, Institutional Review Board, Panel 7, Stanford University, Stanford, CA (2010 - present)
• Chair for Veterans Affairs, Department of Defense and VA Bipolar Disorder Treatment Guidelines (2008 - present)
• Member, Sub Workgroup for Mood Disorders, American Psychiatric Association Diagnostic and Statistical Manual for Mental Disorders 5 (DSM5) (2007 - present)
• Member, Workgroup for Mood Disorders, American Psychiatric Association Diagnostic and Statistical Manual for Mental Disorders 5 (DSM5) (2007 - present)
• Member, American Psychiatric Association Work Group for the Practice Guidelines for Bipolar Disorder (2006 - 2009)

Honors and Awards

• Elected by peers for inclusion, Best Doctors in America® (1996-2010)
• Councilor, Board of Councilors, International Society for Bipolar Disorders (ISBD) (2009 – Present)
• Elected to Fellow, American College of Neuropsychopharmacology (ACNP) (2009 - Present)
• Gerald L. Klerman Senior Investigator Award, Depression and Bipolar Support Alliance (2008)

Professional Education

Postdoctoral Advisees

Victoria Cosgrove

Graduate & Fellowship Program Affiliations

• Neurology and Neurol Sciences
• Neurosciences
• Psychiatry and Behavioral Science

Internet Links

• Bipolar Disorder Research Program

Current Research Interests

Dr. Suppes is the Director of the Bipolar Disorders Research Program at the VA Palo Alto Health Care System. She is a recognized expert on the biology and treatment of bipolar disorder. Her areas of specific expertise include long-term treatment strategies for bipolar disorder, identification and treatment of bipolar II disorder, treatment of those with bipolar disorders and co-morbid conditions, and use of complementary medicine for bipolar disorder. Dr. Suppes has been integrally involved in numerous initiatives to improve evidence based treatment for bipolar disorders, including the Texas Medication Algorithm Project and the American Psychiatric Association guidelines for bipolar disorder. These have been widely disseminated and adopted both nationally and internationally.

Clinical Trials

• Bipolar II Depression: Lithium, SSRI, or the Combination Recruiting
• An RCT of Quetiapine XR Monotherapy and Divalproex Sodium ER Monotherapy for Bipolar Disorder with Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder No longer recruiting
• Divalproex Extended Release and Placebo, Lithium, or Quetiapine for Mania No longer recruiting
• Study of ziprasidone in Bipolar Disorder with Comorbid Lifetime Panic or Generalized Anxiety Disorder No longer recruiting

Publications

• Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany. Post RM, Leverich GS, Altshuler LL, Frye MA, Suppes T, Keck PE, McElroy SL, Nolen WA, Kupka R, Grunze H, Walden J, Rowe M. Int Clin Psychopharmacol. 2011; 26 (2): 96-106
• Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. McElroy SL, Frye MA, Hellemann G, Altshuler L, Leverich GS, Suppes T, Keck PE, Nolen WA, Kupka R, Post RM. J Affect Disord. 2011; 128 (3): 191-8
• Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. Post RM, Altshuler LL, Frye MA, Suppes T, Keck PE, McElroy SL, Leverich GS, Luckenbaugh DA, Rowe M, Pizzarello S, Kupka RW, Grunze H, Nolen WA. J Clin Psychiatry. 2010; 71 (9): 1176-86; quiz 1252-3
• Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. Post RM, Leverich GS, Kupka RW, Keck PE, McElroy SL, Altshuler LL, Frye MA, Luckenbaugh DA, Rowe M, Grunze H, Suppes T, Nolen WA. J Clin Psychiatry. 2010; 71 (7): 864-72
• Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. J Affect Disord. 2010; 121 (1-2): 106-15